This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunning, B. E. Articles by Gerich, J. E. Search for Related Content PubMed PubMed Citation Articles by Dunning, B. E. Articles by Gerich, J. E.

The Role of -Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications

PharmaWrite (B.E.D.), Princeton, New Jersey 08540; and University of Rochester Medical Center (J.E.G.), Rochester, New York 14642

Correspondence: Address all correspondence and requests for reprints to: John E. Gerich, M.D., Professor of Medicine and Program Director, Endocrine-Metabolism Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York 14642. E-mail: john_gerich{at}urmc.rochester.edu

The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic -cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed.

Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving -cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, -cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.

This article has been cited by other articles:

				W. Gu, H. Yan, K. A. Winters, R. Komorowski, S. Vonderfecht, L. Atangan, G. Sivits, D. Hill, J. Yang, V. Bi, et al. Long-Term Inhibition of the Glucagon Receptor with a Monoclonal Antibody in Mice Causes Sustained Improvement in Glycemic Control, with Reversible {alpha}-Cell Hyperplasia and Hyperglucagonemia J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 871 - 881. [Abstract] [Full Text] [PDF]

				K. J. Hare, F. K. Knop, M. Asmar, S. Madsbad, C. F. Deacon, J. J. Holst, and T. Vilsboll Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4679 - 4687. [Abstract] [Full Text] [PDF]

				B. Hellman, A. Salehi, E. Gylfe, H. Dansk, and E. Grapengiesser Glucose Generates Coincident Insulin and Somatostatin Pulses and Antisynchronous Glucagon Pulses from Human Pancreatic Islets Endocrinology, December 1, 2009; 150(12): 5334 - 5340. [Abstract] [Full Text] [PDF]

				R. Guardado-Mendoza, A. M. Davalli, A. O. Chavez, G. B. Hubbard, E. J. Dick, A. Majluf-Cruz, C. E. Tene-Perez, L. Goldschmidt, J. Hart, C. Perego, et al. Pancreatic islet amyloidosis, {beta}-cell apoptosis, and {alpha}-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons PNAS, August 18, 2009; 106(33): 13992 - 13997. [Abstract] [Full Text] [PDF]

				H. Schrader, B. A. Menge, T. G. K. Breuer, P. R. Ritter, W. Uhl, W. E. Schmidt, J. J. Holst, and J. J. Meier Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2857 - 2863. [Abstract] [Full Text] [PDF]

				E. Tuduri, L. Marroqui, S. Soriano, A. B. Ropero, T. M. Batista, S. Piquer, M. A. Lopez-Boado, E. M. Carneiro, R. Gomis, A. Nadal, et al. Inhibitory Effects of Leptin on Pancreatic {alpha}-Cell Function Diabetes, July 1, 2009; 58(7): 1616 - 1624. [Abstract] [Full Text] [PDF]

				S.-S. Chen, T. S. Santomango, P. E. Williams, D. B. Lacy, and O. P. McGuinness Glucagon-mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1172 - E1178. [Abstract] [Full Text] [PDF]

				H. Yan, W. Gu, J. Yang, V. Bi, Y. Shen, E. Lee, K. A. Winters, R. Komorowski, C. Zhang, J. J. Patel, et al. Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 102 - 111. [Abstract] [Full Text] [PDF]

				B. Ahren, A. Schweizer, S. Dejager, B. E. Dunning, P. M. Nilsson, M. Persson, and J. E. Foley Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1236 - 1243. [Abstract] [Full Text] [PDF]

				S. Ali and D. J. Drucker Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E415 - E421. [Abstract] [Full Text] [PDF]

				N. Quoix, R. Cheng-Xue, L. Mattart, Z. Zeinoun, Y. Guiot, M. C. Beauvois, J.-C. Henquin, and P. Gilon Glucose and Pharmacological Modulators of ATP-Sensitive K+ Channels Control [Ca2+]c by Different Mechanisms in Isolated Mouse {alpha}-Cells Diabetes, February 1, 2009; 58(2): 412 - 421. [Abstract] [Full Text] [PDF]

				R. E. Pratley Expanding Treatment Options for Type 2 Diabetes: The Old and the New The Diabetes Educator, January 1, 2009; 35(Supplement_1): 4S - 11S. [Abstract] [Full Text] [PDF]

				B. P. Cummings, E. K. Digitale, K. L. Stanhope, J. L. Graham, D. G. Baskin, B. J. Reed, I. R. Sweet, S. C. Griffen, and P. J. Havel Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1782 - R1793. [Abstract] [Full Text] [PDF]

				I. Quesada, E. Tuduri, C. Ripoll, and A. Nadal Physiology of the pancreatic {alpha}-cell and glucagon secretion: role in glucose homeostasis and diabetes J. Endocrinol., October 1, 2008; 199(1): 5 - 19. [Abstract] [Full Text] [PDF]

				E. Tuduri, E. Filiputti, E. M. Carneiro, and I. Quesada Inhibition of Ca2+ signaling and glucagon secretion in mouse pancreatic {alpha}-cells by extracellular ATP and purinergic receptors Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E952 - E960. [Abstract] [Full Text] [PDF]

				J. Bollyky and C. J. Greenbaum The Role of Glucagon in Postprandial Hyperglycemia The Jury's Still Out J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2879 - 2881. [Full Text] [PDF]